

- 17-Hydroxyprogesterone 560
21-Hydroxylase deficiency 560
- Adolescence 581, 609
Adolescents 599
Adrenal crisis 560
Autonomy 609
- Bariatric surgery 609
Beta-cell preservation 631
Bone disorders 590
Burosumab 590
- Children 590
Clinical trials 631
Closed-loop system 620
Corticotropin-releasing hormone-receptor antagonist 560
Cushing disease 573
Cytochrome P450 family 21 subfamily A member 2 560
- Denosumab 590
Diabetic ketoacidosis 620
- Fludrocortisone 560
- Gene therapy 646
Glucagon-like peptide-1 599
Growth 553, 560
– hormone 553
– – deficiency 553
– – therapy 553
- Hydrocortisone replacement 560
Hypoglycemia 560
- Immunotherapy 631
Islet 658
Isturisa® 573
- Liraglutide 599
Long-acting growth hormone 553
- Male hypogonadism 581
Metabolic and bariatric surgery 609
Modified release hydrocortisone 560
Monogenic disease 646
- Neonatal screening 560
Nevanimibe 560
New testosterone formulations 581
- Obesity 599, 609
Osilodrostat 573
- Pediatric 573
– endocrine disease 646
Pediatrics 581
Pluripotent stem cells 658
Prevention 631
Puberty 560
- Semaglutide 599
SGLT2 inhibitors 620
Short stature 553
Stress dosing 560
- Testosterone replacement therapy 581
Therapy 573
Type 1 diabetes 620, 631, 646, 658
- Vosoritide 590